RecruitingNot applicableNCT04824950
Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL)
Studying Primary mediastinal large B-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Centre Henri Becquerel
- Principal Investigator
- VINCENT CAMUS, MDCentre Henri Becquerel
- Intervention
- Circulating tumor DNA monitoring(other)
- Enrollment
- 87 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2028
Study locations (2)
- Centre Hospitalier Lyon Sud, Lyon, France
- Centre Henri Becquerel, Rouen, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04824950 on ClinicalTrials.govOther trials for Primary mediastinal large B-cell lymphoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE1NCT07168486CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell LymphomasUniversity of Maryland, Baltimore
- RECRUITINGPHASE2NCT06500273Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCLAllogene Therapeutics
- ACTIVE NOT RECRUITINGPHASE1NCT05757700Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell LymphomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1NCT05653271ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell MalignanciesAcepodia Biotech, Inc.
- ACTIVE NOT RECRUITINGNCT06024694Primary Mediastinal Large B-cell Lymphoma With CNS InvolvementIRCCS San Raffaele
- RECRUITINGNCT05366569Bio-CAR-T BS StudyAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
- ACTIVE NOT RECRUITINGPHASE3NCT04759586Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell LymphomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT04745949PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapyM.D. Anderson Cancer Center
See all trials for Primary mediastinal large B-cell lymphoma →